Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Graft-Versus-Host Disease | Research

Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients

Authors: Alain Mina, Lauren Curtis, Kamille West, Yu Ying Yau, Edward W. Cowen, Frances Hakim, Steven Z. Pavletic

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Chronic graft-versus-host disease (GVHD) is a major cause of late morbidity and non-relapse mortality in recipients of allogeneic hematopoietic cell transplantation (HCT). Its biology, however, remains poorly understood, making the studies of its biology and immunomodulatory therapies a difficult task. Such research is often hampered by lymphopenia which is common in these patients and precludes studies of critical cellular subsets across the spectrum of severity of disease. This study explores the potential of leukapheresis to safely acquire and efficiently store immune cells for immunology research in chronic GVHD.

Methods

This is a cross-sectional study in which 132 consecutively accrued patients undergo optional research leukapheresis and a one-week comprehensive outpatient evaluation. Baseline clinical and laboratory data and efficiency of the procedure were reported.

Results

Ninety-four of 132 patients (71%) achieved the goal collection of 2 × 10^9 PBMNCs with a mean volume processed of 4.6 L. Only mild decreases in hemoglobin, platelet, lymphocyte and monocytes were observed. All adverse events were mild (grade 1) and had resolved by the time of discharge from the apheresis unit.

Conclusion

This study demonstrates feasibility, safety, and efficiency of research leukapheresis in a frail patient population. Results presented promote leukapheresis as a standard research practice option in studies of chronic GVHD in humans which may expedite advances in our understanding of this complex multisystem disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arai S, Arora M, Wang T, et al. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21:266–74.CrossRefPubMed Arai S, Arora M, Wang T, et al. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21:266–74.CrossRefPubMed
2.
go back to reference Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377:2565–79.CrossRefPubMed Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377:2565–79.CrossRefPubMed
3.
go back to reference Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Francis K, Dehipawala S, Rotta M. (2021) Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis. Transplant Cell Ther 27:504.e1-504.e6. Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Francis K, Dehipawala S, Rotta M. (2021) Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis. Transplant Cell Ther 27:504.e1-504.e6.
5.
go back to reference Im A, Hakim FT, Pavletic SZ. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia. 2017;31:543–54.CrossRefPubMed Im A, Hakim FT, Pavletic SZ. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia. 2017;31:543–54.CrossRefPubMed
6.
go back to reference Hakim FT, Memon S, Jin P, et al. Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. J Immunol. 2016;197:3490–503.CrossRefPubMed Hakim FT, Memon S, Jin P, et al. Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. J Immunol. 2016;197:3490–503.CrossRefPubMed
7.
go back to reference Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:211–34.CrossRefPubMed Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:211–34.CrossRefPubMed
8.
go back to reference Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128:130–7.CrossRefPubMedPubMedCentral Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128:130–7.CrossRefPubMedPubMedCentral
9.
go back to reference Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, Toubert A, Zeiser R, Galimberti S. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Front Immunol. 2020;11:578314.CrossRefPubMedPubMedCentral Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, Toubert A, Zeiser R, Galimberti S. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Front Immunol. 2020;11:578314.CrossRefPubMedPubMedCentral
12.
go back to reference Grkovic L, Baird K, Steinberg SM, et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia. 2012;26:633–43.CrossRefPubMed Grkovic L, Baird K, Steinberg SM, et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia. 2012;26:633–43.CrossRefPubMed
13.
go back to reference Kuzmina Z, Gounden V, Curtis L, et al. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Am J Hematol. 2015;90:114–9.CrossRefPubMed Kuzmina Z, Gounden V, Curtis L, et al. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Am J Hematol. 2015;90:114–9.CrossRefPubMed
14.
15.
go back to reference Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127:646–57.CrossRefPubMedPubMedCentral Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127:646–57.CrossRefPubMedPubMedCentral
16.
go back to reference Rieger K. Mucosal FOXP3 + regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006;107:1717–23.CrossRefPubMed Rieger K. Mucosal FOXP3 + regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006;107:1717–23.CrossRefPubMed
17.
go back to reference Gołąb K, Grose R, Trzonkowski P, et al. Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders. Oncotarget. 2016;7:79474–84.CrossRefPubMedPubMedCentral Gołąb K, Grose R, Trzonkowski P, et al. Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders. Oncotarget. 2016;7:79474–84.CrossRefPubMedPubMedCentral
18.
go back to reference DeFilipp Z, Alousi AM, Pidala JA, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5:4278–84.CrossRefPubMedPubMedCentral DeFilipp Z, Alousi AM, Pidala JA, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5:4278–84.CrossRefPubMedPubMedCentral
19.
go back to reference Radwanski K, Burgstaler E, Weitgenant J, Dale H, Heber C, Winters J. Pilot study of a new online extracorporeal photopheresis system in patients with steroid refractory or dependent chronic graft vs host disease. J Clin Apher. 2020;35:342–50.CrossRefPubMedPubMedCentral Radwanski K, Burgstaler E, Weitgenant J, Dale H, Heber C, Winters J. Pilot study of a new online extracorporeal photopheresis system in patients with steroid refractory or dependent chronic graft vs host disease. J Clin Apher. 2020;35:342–50.CrossRefPubMedPubMedCentral
20.
go back to reference Liu C, Shah K, Dynis M, Eby CS, Grossman BJ. Linear relationship between lymphocyte counts in peripheral blood and buffy coat collected during extracorporeal photopheresis. Transfus (Paris). 2013;53:2635–43.CrossRef Liu C, Shah K, Dynis M, Eby CS, Grossman BJ. Linear relationship between lymphocyte counts in peripheral blood and buffy coat collected during extracorporeal photopheresis. Transfus (Paris). 2013;53:2635–43.CrossRef
21.
go back to reference Foss F, Gorgun G, Miller K. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29:719–25.CrossRefPubMed Foss F, Gorgun G, Miller K. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29:719–25.CrossRefPubMed
22.
go back to reference Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft- versus -host disease: evidence and opinion. Ther Adv Hematol. 2013;4:320–34.CrossRefPubMedPubMedCentral Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft- versus -host disease: evidence and opinion. Ther Adv Hematol. 2013;4:320–34.CrossRefPubMedPubMedCentral
23.
go back to reference Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016;34:1112–21.CrossRefPubMedPubMedCentral Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016;34:1112–21.CrossRefPubMedPubMedCentral
24.
go back to reference Yamanaka I, Yamauchi T, Henzan T, et al. Optimization of lymphapheresis for manufacturing autologous CAR-T cells. Int J Hematol. 2021;114:449–58.CrossRefPubMed Yamanaka I, Yamauchi T, Henzan T, et al. Optimization of lymphapheresis for manufacturing autologous CAR-T cells. Int J Hematol. 2021;114:449–58.CrossRefPubMed
25.
27.
go back to reference Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385:567–9.CrossRefPubMed Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385:567–9.CrossRefPubMed
29.
go back to reference Pavletic SZ, Martin PJ, Schultz KR, Lee SJ. The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. Transpl Cell Ther. 2021;27:448–51.CrossRef Pavletic SZ, Martin PJ, Schultz KR, Lee SJ. The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. Transpl Cell Ther. 2021;27:448–51.CrossRef
Metadata
Title
Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients
Authors
Alain Mina
Lauren Curtis
Kamille West
Yu Ying Yau
Edward W. Cowen
Frances Hakim
Steven Z. Pavletic
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03708-w

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.